IGF-1 DES
Begrenzte ForschungTruncated IGF-1 Analog | Localized Muscle Growth
IGF-1 DES (Des(1-3) IGF-1) is a truncated analog of insulin-like growth factor-1, missing the first three N-terminal amino acids.
Molekulare und Forschungsdaten
- Molekulargewicht
- ~7,000 Da
- Halbwertszeit
- 20-30 minutes
- Primäre Ziele
- igf1, mtor
- Wege (Forschung)
- injectable
- Lagerung
- Lyophilized: -20C. Reconstituted: 2-8C, use within 7 days (BAC water)
Overview
IGF-1 DES (Des(1-3) IGF-1) is a truncated analog of insulin-like growth factor-1, missing the first three N-terminal amino acids. This structural modification eliminates binding to IGF binding proteins (IGFBPs), meaning 100% of the peptide is bioactive rather than being sequestered in circulation. The result is approximately 10x greater potency than native IGF-1, but with an extremely short half-life of 20-30 minutes. This short duration of action is considered a feature rather than a limitation – it allows for site-specific injection into target muscles immediately post-workout, promoting localized growth with reduced systemic exposure.
Mechanism of action
IGF-1 DES activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt/mTOR and MAPK/ERK signaling pathways, driving both muscle hypertrophy and hyperplasia. Because it lacks the tripeptide Gly-Pro-Glu at the N-terminus, it cannot bind to IGFBPs that normally sequester ~98% of circulating IGF-1. This means the entire administered dose remains bioavailable. The very short half-life confines its activity to the local injection site, where it stimulates satellite cell proliferation and differentiation, protein synthesis, and nutrient uptake in the targeted muscle tissue.
Key research findings
- Approximately 10x more potent than native IGF-1
- 100% bioactive – does not bind to IGF binding proteins
- Extremely short half-life enables localized, site-specific action
- Promotes satellite cell activation for muscle hyperplasia
- Minimal systemic exposure compared to IGF-1 LR3
Research applications
Muscle Growth
- Localized Hypertrophy — Site-specific muscle growth via direct intramuscular injection into target muscle post-workout.
- Hyperplasia — Stimulates satellite cell proliferation and differentiation, potentially creating new muscle fibers.
- Recovery — Accelerates local tissue recovery in the injected muscle group after training.
Tissue Repair
- Local Tissue Repair — Promotes repair and regeneration at the injection site through IGF-1R activation.
IGF-1 DES Häufig gestellte Fragen
Why is IGF-1 DES injected directly into muscles?+
IGF-1 DES has a 20-30 minute half-life and doesn't bind IGF binding proteins, making it 10x more potent but short-acting. Direct intramuscular injection confines its activity to the targeted muscle immediately post-workout, enabling localized hypertrophy without systemic IGF-1 excess.
Will IGF-1 DES cause hypoglycemia?+
Yes. IGF-1 DES lowers blood glucose by promoting glucose uptake into muscle tissue. You must consume 20-40g of fast carbohydrates immediately after injection. Monitor blood glucose early in use and never inject before sleep due to overnight hypoglycemia risk.
Can I use IGF-1 DES if I'm on a keto diet?+
Not safely. The mandatory carbohydrate intake after IGF-1 DES injection will break ketosis. If keto is your goal, use alternatives like GH or ipamorelin instead. The post-injection carbs are non-negotiable for safety.
Does IGF-1 DES cause cancer risk?+
IGF-1 promotes cell proliferation, and elevated systemic IGF-1 is linked to multiple cancers in the UK Biobank study. DES minimizes systemic exposure through its short half-life and local injection, but cancer risk remains a theoretical concern with any IGF-1 product.
References
- [1]The isolation and characterization of a naturally occurring truncated form of IGF-I in human brainBiochemical and Biophysical Research Communications
- [2]Des(1-3)IGF-I: A truncated form of insulin-like growth factor-I that has greatly enhanced activity in promoting growthJournal of Molecular Endocrinology
- [3]Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated ratsBiochemical Journal
- [4]Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK BiobankCancer Research
Verwandte Peptide
ACE-031
Emerging researchMyostatin Inhibitor | Experimental Muscle Growth
ACE-031 is a soluble form of the activin type IIB receptor (ActRIIB) fused to an IgG1 Fc domain.
CJC-1295
In clinical trialsLangwirkendes GHRH-Analog
CJC-1295 ist ein synthetisches Analog des Wachstumshormonfeinfrequenzlösungs-Hormons (GHRH), das für eine dramatisch verlängerte Halbwertzeit entwickelt wurde und auf seine Fähigkeit untersucht wird, Wachstumshormonspiegel und IGF-1-Spiegel zu erhöhen.
CJC-1295 with DAC
Well studiedLong-Acting Growth Hormone Releasing Hormone Analog | Extended Release
Modified growth hormone releasing hormone engineered for extended duration via albumin-binding technology. DAC binds to albumin, extending half-life and providing continuous GHRH receptor stimulation.
CJC/IPA Protocol
Well studiedGHRH/GHRP Combination | Growth Hormone Optimization
A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms.